ArticleFrontiers in medicine2025
Case Report: Pathological features of explanted native lungs in a patient with end stage lung disease after resolution of severe COVID19 who underwent successful lung transplantation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the pandemic of COVID-19, lots of features of this disease have been discovered. However, the lung pathology and the correlated clinical features of the patients who recovered from the severe state of COVID-19 are still largely unknown. Especially for those who underwent diffuse alveolar damage (DAD), most of the morphological data were obtained from the autopsy specimens or biopsy samples. In the present report, the pathologic changes in the lungs of a patient who had successfully received lung transplantation at the recovery stage of severe COVID-19 were described. Diffuse alveolar damage, hyperplasia of interstitial fibroblast and alveolar type II epithelial cells, and the filling of macrophages in alveoli were observed. Hyperemia and thickening of blood vessels and interstitial lymphocytic inflammation were also prominent. SARS-COV-2 nuclear capsid was detected spotty in the alveolar epithelial after several times' negative nucleic acid results from his pharyngeal swab specimens. Evidence of combined virus infection, such as Cytomegalovirus, could also be found. A few eosinophils were found in the parenchymal of the lung, which combined with the elevated eosinophils in the blood, might indicate a recovery of this patient. This rare case provides a chance for us to observe the pathological changes in the diffuse fibrosis stage of severe COVID-19, which might help us to further understand how pulmonary fibrosis forms after severe pathogen infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.